Clinical Trials Insight: 700028165
Latest Information Update: 29 Aug 2008
Price :
$35 *
At a glance
- Drugs Tretazicar/caricotamide (Primary) ; Caricotamide; Sorafenib; Tretazicar
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Protherics
- 27 Aug 2008 Status changed from planning to recruiting, as reported in a Protherix media release.
- 27 Aug 2008 Planned end date is 1 Jul 2009, according to a Protherix media release.
- 06 Nov 2007 New trial record.